Blocking IL-17A activity shows a therapeutic efficacy against both cholestatic and hepatotoxic hepatic fibrosis and results in a shift from the suppressive immune response toward a Th1 response in the fibrotic liver. This evidence concerns the gene IL17A and Hepatic fibrosis.